Wells Fargo & Company Indaptus Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INDP
# of Institutions
20Shares Held
600KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA256KShares$299,8300.0% of portfolio
-
Investment House LLC Las Vegas, NV102KShares$119,8510.01% of portfolio
-
Geode Capital Management, LLC Boston, MA59.3KShares$69,3910.0% of portfolio
-
Strategy Asset Managers LLC45.3KShares$53,0430.02% of portfolio
-
Pine Valley Investments LTD Liability CO Marlton, NJ44.1KShares$51,5790.01% of portfolio
About Indaptus Therapeutics, Inc.
- Ticker INDP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,258,600
- Market Cap $9.66M
- Description
- Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...